Advocacy, Biologics1 week agoThe Next Front in Drug Pricing: What Medicare Drug Negotiation Means for Buy-and-Bill Infusion Practices
Advocacy, Biologics4 weeks agoHarnessing Patient Experience Data to Improve Infusion Practice Performance
Advocacy, Biologics1 month ago2026 PBM Formulary Exclusions: What Independent Practices Need to Know About Biosimilars, Net Pricing, and Market Access
Advocacy, Biologics3 months agoFaster Rituximab Infusions in Rheumatology: Evidence Supports Safe, Efficient Care Delivery
Advocacy, Biologics4 months agoOptimizing Infusion Center Capacity in 2026: Strategies to Do More Without Expanding Footprint
Advocacy, Biologics4 months agoBiosimilar Adoption in 2026: What Every Specialty Practice Needs to Know
Advocacy5 months agoVertical Integration and the Future of Buy-and-Bill: How Wholesalers Are Rewriting Market Access
Advocacy7 months agoAccumulator and Maximizer Programs: What Specialty Providers Need to Know About the Hidden Costs for Patients
Advocacy7 months agoBeyond the Bag: Building Operational Resilience in Your Buy-and-Bill Infusion Model
Advocacy8 months agoPrivate Labels, Public Consequences: Making Sense of the Stelara Biosimilar Market in 2025
Advocacy8 months agoIs Your Infusion Suite Future-Ready? Infrastructure, Staffing, and Payer Trends to Watch
Advocacy11 months agoEnhancing Neurology Practice Efficiency: How Group Purchasing Can Support Better Care Delivery
Advocacy1 year agoPerformance Metrics in Rheumatology Practices: Strategies for Measuring Success with Remedy GPO
